Business
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell lines and NSCLC animal modelsSuperior anti-tumor activity of ARR-002 in ovarian cancer models compared to single-target or bivalent approaches with favorable tolerability underscores best-in-disease ADC potential NEWTOWN SQUARE, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company
About this update from Arrivent Biopharma, Inc.
[{"type":"image","alt":"ArriVent BioPharma, Inc.","displaySize":"","headline":null,"caption":"ArriVent BioPharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":54,"url":"https://media.zenfs.com/en/globenewswire.com/ee721b323366bda6b0e387ffd6ff88f3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pbKJui9qpentd1WpEbYjVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/ee721b323366bda6b0e387ffd6ff88f3","width":300,"height":54}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell lines and NSCLC animal models","length":173,"tagName":"p"}]},{"val":[{"type":"text","content":"Superior anti-tumor activity of ARR-002 in ovarian cancer models compared to single-target or bivalent approaches with favorable tolerability underscores best-in-disease ADC potential","length":183,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":356,"olType":false},{"type":"text","content":"NEWTOWN SQUARE, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced two poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California April 17-22.","length":405,"tagName":"p"},{"type":"text","content":"Preclinical findings for EGFR inhibitor firmonertinib will highlight high resolution crystal structure data supporting the ongoing pivotal Phase 3 study in frontline EGFR exon 20 insertion mutant non-small cell lung cancer (NSCLC). ArriVent in partnership with Aarvik Therapeutics, Inc. (Aarvik) will also present preclinical data on ARR-002, also known as AV-P138-ADC, a novel dual-target MUC16/NaPi2b tetravalent antibody drug conjugate (ADC), characterizing its superior ADC potential in ovarian and endometrial cancers and planned advancement towards clinical evaluation. Data for ARR-002 will also be presented as part of an oral presentation by Aarvik at the Clinical Research Mini Symposium.","length":698,"tagName":"p"},{"type":"text","content":"Abstract Highlights and Presentation Det...